Gérald Cruciani

Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment

Anna S. Monzel, R. Krüger, J. Modamio, 2021, Movement disorders : official journal of the Movement Disorder Society.

Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening

R. Krüger, P. Heutink, P. Antony, 2021, Scientific reports.

Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function

R. Krüger, N. Casadei, P. Antony, 2021, Scientific Reports.

Gene-corrected Parkinson’s disease neurons show the A30P alpha-synuclein point mutation leads to reduced neuronal branching and function

R. Krüger, P. Antony, Paul M. A. Antony, 2020, bioRxiv.

A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease

P. May, W. Wurst, R. Krüger, 2020, Science Translational Medicine.

Parkinson’s disease phenotypes in patient specific brain organoids are improved by HP-β-CD treatment

Anna S. Monzel, R. Krüger, C. Klein, 2019, bioRxiv.

Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson’s Disease Point Mutation A30P

R. Krüger, P. Antony, J. Schwamborn, 2020, Cells.

Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson's disease patient carrying the heterozygous p.A30P mutation in SNCA.

R. Krüger, Peter A. Barbuti, F. Massart, 2020, Stem cell research.

Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35.

R. Krüger, G. Mellick, Peter A. Barbuti, 2020, Stem cell research.